|
1
|
Armstrong TS, Wen PY, Gilbert MR and
Schiff D: Management of treatment-associated toxicites of
anti-angiogenic therapy in patients with brain tumors. Neuro Oncol.
14:1203–1214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2019. View Article : Google Scholar
|
|
4
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenueto a cure for malignant glioma. CA Cancer
J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakada M, Nakada S, Demuth T, Tran NL,
Hoelzinger DB and Berens ME: Molecular targets of glioma invasion.
Cell Mol Life Sci. 64:458–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Graña X, Claudio PP, De Luca A, Sang N and
Giordano A: PISSLRE, a human novel CDC2-related protein kinase.
Oncogene. 9:2097–2103. 1994.PubMed/NCBI
|
|
7
|
Brambilla R and Draetta G: Molecular
cloning of PISSLRE, a novel putative member of the cdk family of
protein serine/threonine kinases. Oncogene. 9:3037–3041.
1994.PubMed/NCBI
|
|
8
|
Li S, MacLachlan TK, De Luca A, Claudio
PP, Condorelli G and Giordano A: The cdc-2-related kinase, PISSLRE,
is essential for cell growth and acts in G2 phase of the cell
cycle. Cancer Res. 55:3992–3995. 1995.PubMed/NCBI
|
|
9
|
Iorns E, Turner NC, Elliott R, Syed N,
Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A:
Identification of CDK10 as an important determinant of resistance
to endocrine therapy for breast cancer. Cancer Cell. 13:91–104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You Y, Yang W, Wang Z, Zhu H, Li H, Lin C
and Ran Y: Promoter hypermethylation contributes to the frequent
suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Cell Oncol (Dordr). 36:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong
Q, Tai S, Li H and Cui YF: CDK10 functions as a tumor suppressor
gene and regulates survivability of biliary tract cancer cells.
Oncol Rep. 27:1266–1276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong XY, Xu XX, Yu JH, Jiang GX, Yu Y,
Tai S, Wang ZD and Cui YF: Clinical and biological significance of
Cdk10 in hepatocellular carcinoma. Gene. 498:68–74. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You Y, Li H, Qin X, Zhang Y, Song W, Ran Y
and Gao F: Decreased CDK10 expression correlates with lymph node
metastasis and predicts poor outcome in breast cancer patients-a
short report. Cell Oncol. 38:485–491. 2015. View Article : Google Scholar
|
|
14
|
Hong CQ, Zhang F, You YJ, Qiu WL, Giuliano
AE, Cui XJ, Zhang GJ and Cui YK: Elevated C1orf63 expression is
correlated with CDK10 and predicts better outcome for advanced
breast cancers: A retrospective study. BMC Cancer. 15:5482015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
You Y, Liu J, Wang Z, Zhang Y, Ran Y, Guo
X, Liu H and Wang H: The enhancement of radiosensitivity in human
esophageal squamous cell carcinoma cells by zoledronic acid and its
potential mechanism. Cytotechnology. 66:17–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
You Y, Yang W, Qin X, Wang F, Li H, Lin C,
Li W, Gu C, Zhang Y and Ran Y: ECRG4 acts as a tumor suppressor and
as a determinant of chemotherapy resistance in human nasopharyngeal
carcinoma. Cell Oncol. 38:205–214. 2015. View Article : Google Scholar
|
|
17
|
Lin C, Xin S, Qin X, Li H, Lin L and You
Y: Zoledronic acid suppresses metastasis of esophageal squamous
cell carcinoma cells through upregulating the tight junction
protein occludin. Cytotechnology. 68:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae
JA, Yoon S, Ryu HH, Jung S, Kim KK, et al: KITENIN promotes glioma
invasiveness and progression, associated with the induction of EMT
and stemness markers. Oncotarget. 6:3240–3253. 2015.PubMed/NCBI
|
|
19
|
Pang H, Zheng Y, Zhao Y, Xiu X and Wang J:
miR-590-3p suppresses cancer cell migration, invasion and
epithelial-mesenchymal transition in glioblastoma multiforme by
targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 468:739–745.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagaishi M, Paulus W, Brokinkel B, Vital
A, Tanaka Y, Nakazato Y, Giangaspero F and Ohgaki H:
Transcriptional factors for epithelial-mesenchymal transition are
associated with mesenchymal differentiation in gliosarcoma. Brain
Pathol. 22:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myung J, Cho BK, Kim YS and Park SH: Snail
and Cox-2 expressions are associated with WHO tumor grade and
survival rate of patients with gliomas. Neuropathology. 30:224–231.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu T, Zhou M, Peng L, Kong S, Miao R, Shi
Y, Sheng H and Li L: Upregulation of CD147 promotes cell invasion,
epithelial-to-mesenchymal transition and activates MAPK/ERK
signaling pathway in colorectal cancer. Int J Clin Exp Pathol.
7:7432–7441. 2014.PubMed/NCBI
|
|
25
|
Kimura Y, Shiozaki H, Hirao M, Maeno Y,
Doki Y, Inoue M, Monden T, Ando-Akatsuka Y, Furuse M, Tsukita S and
Monden M: Expression of occludin, tight-junction-associated
protein, in human digestive tract. Am J Pathol. 151:45–54.
1997.PubMed/NCBI
|
|
26
|
Martin TA, Mansel RE and Jiang WG: Loss of
occludin leads to the progression of human breast cancer. Int J Mol
Med. 26:723–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tobioka H, Isomura H, Kokai Y, Tokunaga Y,
Yamaguchi J and Sawada N: Occludin expression decreases with the
progression of human endometrial carcinoma. Hum Pathol. 35:159–164.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Wade P, Mandell KJ, Akyildiz A,
Parkos CA, Mrsny RJ and Nusrat A: Raf 1 represses expression of the
tight junction protein occludin via activation of the zinc-finger
transcription factor slug. Oncogene. 26:1222–1230. 2007. View Article : Google Scholar : PubMed/NCBI
|
